

Alan Simon Pickard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/308865/publications.pdf>

Version: 2024-02-01

161
papers

9,285
citations

57631

44
h-index

43802

91
g-index

165
all docs

165
docs citations

165
times ranked

14817
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining EQ-5D-5L items into a level summary score: demonstrating feasibility using non-parametric item response theory using an international dataset. <i>Quality of Life Research</i> , 2022, 31, 11-23.	1.5	10
2	Developing a New Generic Health and Wellbeing Measure: Psychometric Survey Results for the EQ-HWB. <i>Value in Health</i> , 2022, 25, 525-533.	0.1	25
3	Development of a measure of prescriber satisfaction with academic detailing: the PSAD. <i>Drugs in Context</i> , 2022, 11, 1-12.	1.0	2
4	Time-Specific Differences in Stated Preferences for Health in the United States. <i>Medical Care</i> , 2022, Publish Ahead of Print, .	1.1	0
5	Pragmatic Clinical Trial to Improve Patient Experience Among Adults During Transitions from Hospital to Home: the PARTNER study. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	0
6	The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results. <i>Value in Health</i> , 2022, 25, 482-491.	0.1	45
7	Generation, Selection, and Face Validation of Items for a New Generic Measure of Quality of Life: The EQ-HWB. <i>Value in Health</i> , 2022, 25, 512-524.	0.1	12
8	A Comparison of a Preliminary Version of the EQ-HWB Short and the 5-Level Version EQ-5D. <i>Value in Health</i> , 2022, 25, 534-543.	0.1	7
9	The Development of the EQ-5D-5L and its Value Sets. , 2022, , 1-12.		8
10	The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	1.0	2
11	US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. <i>Quality of Life Research</i> , 2021, 30, 803-816.	1.5	88
12	Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off. <i>Quality of Life Research</i> , 2021, 30, 1433-1444.	1.5	19
13	Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality. <i>European Journal of Health Economics</i> , 2021, 22, 17-33.	1.4	2
14	Secondary Effects of an Opioid-Focused Academic Detailing Program on Non-Opioid Controlled Substance Prescribing in Primary Care. <i>Substance Abuse</i> , 2021, 42, 962-967.	1.1	1
15	A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L. <i>Journal of General Internal Medicine</i> , 2021, 36, 1292-1301.	1.3	51
16	Feasibility and acceptability of virtual academic detailing on opioid prescribing. <i>International Journal of Medical Informatics</i> , 2021, 147, 104365.	1.6	10
17	United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument. <i>Medical Decision Making</i> , 2021, 41, 485-501.	1.2	12
18	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021, 22, 723-733.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. <i>European Journal of Health Economics</i> , 2021, 22, 1301-1309.	1.4	3
20	The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. <i>Value in Health</i> , 2021, 24, 862-873.	0.1	14
21	General population normative data for the EQ-5D-3L in the five largest European economies. <i>European Journal of Health Economics</i> , 2021, 22, 1467-1475.	1.4	22
22	Hospitalizations for opioid-related overdose and timing of concurrent opioid and benzodiazepine use: A nested case-control study. <i>Pharmacotherapy</i> , 2021, 41, 722-732.	1.2	2
23	Academic detailing interventions for opioid-related outcomes: a scoping review. <i>Drugs in Context</i> , 2021, 10, 1-20.	1.0	4
24	Combating the opioid epidemic in the United States. <i>Drugs in Context</i> , 2021, 10, 1-3.	1.0	2
25	Practice change intentions after academic detailing align with subsequent opioid prescribing. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 1001-1008.	0.7	7
26	Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. <i>Value in Health</i> , 2020, 23, 1235-1245.	0.1	58
27	Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. <i>Quality of Life Research</i> , 2020, 29, 2651-2660.	1.5	17
28	Using Both Time Tradeoff and Discrete Choice Experiments in Valuing the EQ-5D: Impact of Model Misspecification on Value Sets. <i>Medical Decision Making</i> , 2020, 40, 483-497.	1.2	2
29	Identification of barriers to safe opioid prescribing in primary care: a qualitative analysis of field notes collected through academic detailing. <i>British Journal of General Practice</i> , 2020, 70, e589-e597.	0.7	12
30	Management of pyrexia in metastatic melanoma patients: A real-world clinical experience survey study. <i>Journal of Clinical Oncology</i> , 2020, 38, e22102-e22102.	0.8	1
31	Development of an Instrument to Assess the Perceived Effectiveness of Academic Detailing. <i>Journal of Continuing Education in the Health Professions</i> , 2020, 40, 235-241.	0.4	4
32	United States Valuation of EQ-5D-5L Health States Using an International Protocol. <i>Value in Health</i> , 2019, 22, 931-941.	0.1	204
33	The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30. <i>MDM Policy and Practice</i> , 2019, 4, 238146831984253.	0.5	16
34	A comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017. <i>Quality of Life Research</i> , 2019, 28, 3065-3069.	1.5	14
35	Older Medicare Beneficiaries Frequently Continue Medications with Limited Benefit Following Hospice Admission. <i>Journal of General Internal Medicine</i> , 2019, 34, 2029-2037.	1.3	10
36	U.K. utility weights for the EORTC QLU-C10D. <i>Health Economics (United Kingdom)</i> , 2019, 28, 1385-1401.	0.8	30

#	ARTICLE	IF	CITATIONS
37	Design of the patient navigator to Reduce Readmissions (PARtNER) study: A pragmatic clinical effectiveness trial. <i>Contemporary Clinical Trials Communications</i> , 2019, 15, 100420.	0.5	9
38	Exploring the Internal Structure of the EQ-5D Using Non-Preference-Based Methods. <i>Value in Health</i> , 2019, 22, 527-536.	0.1	14
39	Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , 2019, 22, 267-275.	0.1	98
40	The EQ-5D and the EuroQol Group. <i>Value in Health</i> , 2019, 22, 21-22.	0.1	18
41	Latent Class Models Reveal Poor Agreement between Discrete-Choice and Time Tradeoff Preferences. <i>Medical Decision Making</i> , 2019, 39, 421-436.	1.2	5
42	The Role of Personality in Treatment-Related Outcome Preferences Among Pharmacy Students. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 6891.	0.7	4
43	Use of Nonpalliative Medications Following Burdensome Health Care Transitions in Hospice Patients. <i>Medical Care</i> , 2019, 57, 13-20.	1.1	6
44	Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2019, 37, 105-116.	1.7	13
45	Health outcomes in spinal muscular atrophy type 1 following AVXS101 gene replacement therapy. <i>Pediatric Pulmonology</i> , 2019, 54, 179-185.	1.0	142
46	Medicare Part D Use of Older Medicare Beneficiaries Admitted to Hospice. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 937-944.	1.3	6
47	3L, 5L, What the L? A NICE Conundrum. <i>Pharmacoeconomics</i> , 2018, 36, 637-640.	1.7	28
48	Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. <i>Pharmacoeconomics</i> , 2018, 36, 225-238.	1.7	77
49	Lifestyle-related attitudes: do they explain self-rated health and life-satisfaction?. <i>Quality of Life Research</i> , 2018, 27, 1227-1235.	1.5	10
50	Value of transfusion independence in severe aplastic anemia from patients' perspectives - a discrete choice experiment. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 13.	0.9	5
51	EQ-5D-Y for the assessment of health-related quality of life among Taiwanese youth with mild-to-moderate chronic kidney disease. <i>International Journal for Quality in Health Care</i> , 2018, 30, 298-305.	0.9	19
52	Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. <i>Medical Decision Making</i> , 2018, 38, 968-982.	1.2	25
53	Valuation of the EQ-5D-5L in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0209344.	1.1	38
54	Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 265-279.	0.5	8

#	ARTICLE	IF	CITATIONS
55	Comparative effectiveness and patient-centered outcomes research: enhancing uptake and use by patients, clinicians and payers. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 177-180.	0.6	4
56	Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 167-175.	0.6	1
57	Comparative Effectiveness of Long-Acting Beta ₂ -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease. <i>Pharmacotherapy</i> , 2017, 37, 447-455.	1.2	18
58	Choice Blindness and Health-State Choices among Adolescents and Adults. <i>Medical Decision Making</i> , 2017, 37, 680-687.	1.2	6
59	Patient Experience-based Value Sets. <i>Medical Care</i> , 2017, 55, 979-984.	1.1	10
60	Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. <i>European Journal of Health Economics</i> , 2017, 18, 967-977.	1.4	8
61	Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β_2 -Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid. <i>Annals of Pharmacotherapy</i> , 2017, 51, 945-953.	0.9	19
62	Transforming Latent Utilities to Health Utilities: East Does Not Meet West. <i>Health Economics (United Kingdom)</i> 37(10):1033-1050, 2017	0.8	13
63	EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. <i>Journal of Medical Economics</i> , 2017, 20, 19-27.	1.0	18
64	The societal cost of heroin use disorder in the United States. <i>PLoS ONE</i> , 2017, 12, e0177323.	1.1	48
65	Engaging Patients and Caregivers to Design Transitional Care Management Services at a Minority Serving Institution. <i>Journal of Health Care for the Poor and Underserved</i> , 2016, 27, 352-365.	0.4	13
66	Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer. <i>Clinical Therapeutics</i> , 2016, 38, 769-777.	1.1	37
67	A Cross Sectional and Longitudinal Study of Pharmacy Student Perceptions of Readiness to Serve Diverse Populations. <i>American Journal of Pharmaceutical Education</i> , 2016, 80, 62.	0.7	12
68	Order of Presentation of Dimensions Does Not Systematically Bias Utility Weights from a Discrete Choice Experiment. <i>Value in Health</i> , 2016, 19, 1033-1038.	0.1	20
69	Respiratory and Bronchitic Symptoms Predict Intention to Quit Smoking among Current Smokers with, and at Risk for, Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1490-1496.	1.5	15
70	Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 441-448.	2.0	111
71	Developing a Valuation Function for the Preference-Based Multiple Sclerosis Index: Comparison of Standard Gamble and Rating Scale. <i>PLoS ONE</i> , 2016, 11, e0151905.	1.1	7
72	Using linked electronic data to validate algorithms for health outcomes in administrative databases. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 359-366.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Emergence of BCR-ABL Kinase Domain Mutations Associated with Newly Diagnosed Chronic Myeloid Leukemia: A Meta-Analysis of Clinical Trials of Tyrosine Kinase Inhibitors. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 114-122.	0.5	19
74	Validity of EQ-5D-5L in stroke. <i>Quality of Life Research</i> , 2015, 24, 845-850.	1.5	167
75	Positive Outcomes of Varicose Vein Surgery: The Patient Perspective. <i>Patient</i> , 2015, 8, 329-337.	1.1	3
76	Do health preferences contradict ordering of EQ-5D labels?. <i>Quality of Life Research</i> , 2015, 24, 1759-1765.	1.5	13
77	Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. <i>Quality of Life Research</i> , 2015, 24, 1555-1563.	1.5	110
78	Is it Time to Update Societal Value Sets for Preference-Based Measures of Health?. <i>Pharmacoeconomics</i> , 2015, 33, 191-192.	1.7	7
79	A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). <i>Pharmacoeconomics</i> , 2015, 33, 867-877.	1.7	45
80	Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. <i>Value in Health Regional Issues</i> , 2014, 4, 19-23.	0.5	30
81	Stakeholder Views on Pharmacogenomic Testing. <i>Pharmacotherapy</i> , 2014, 34, 151-165.	1.2	43
82	US Valuation of Health Outcomes Measured Using the PROMIS-29. <i>Value in Health</i> , 2014, 17, 846-853.	0.1	117
83	Drugs Associated with Adverse Events in Children and Adolescents. <i>Pharmacotherapy</i> , 2014, 34, 918-926.	1.2	21
84	Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. <i>Medical Care</i> , 2014, 52, 935-943.	1.1	38
85	Evaluating Equivalency Between Response Systems. <i>Medical Care</i> , 2014, 52, 385.	1.1	0
86	Evaluating change using patient-reported outcome measures in knee replacement: the complementary nature of the EQ-5D index and VAS scores. <i>European Journal of Health Economics</i> , 2014, 15, 489-496.	1.4	18
87	Using existing data to identify candidate items for a health state classification system in multiple sclerosis. <i>Quality of Life Research</i> , 2014, 23, 1445-1457.	1.5	19
88	Impact of Acute Bleeding on Daily Activities of Patients with Congenital Hemophilia with Inhibitors and Their Caregivers and Families: Observations from the Dosing Observational Study in Hemophilia (DOSE). <i>Value in Health</i> , 2014, 17, 744-748.	0.1	20
89	Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form. <i>BMC Medical Research Methodology</i> , 2014, 14, 78.	1.4	46
90	Health problems are more common, but less severe when measured using newer EQ-5D versions. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 93-99.	2.4	57

#	ARTICLE	IF	CITATIONS
91	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. <i>Quality of Life Research</i> , 2013, 22, 1717-1727.	1.5	1,082
92	Evaluation of content on EQ-5D as compared to disease-specific utility measures. <i>Quality of Life Research</i> , 2013, 22, 853-874.	1.5	26
93	The effect of chronic conditions on stated preferences for health. <i>European Journal of Health Economics</i> , 2013, 14, 697-702.	1.4	23
94	Pharmacoeconomics of Hematopoietic Stem Cell Mobilization: An Overview of Current Evidence and Gaps in the Literature. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1301-1309.	2.0	23
95	US Valuation of the SF-6D. <i>Medical Decision Making</i> , 2013, 33, 793-803.	1.2	60
96	Comparison of US Panel Vendors for Online Surveys. <i>Journal of Medical Internet Research</i> , 2013, 15, e260.	2.1	96
97	Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). <i>Journal of Blood Medicine</i> , 2012, 3, 131.	0.7	8
98	Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 19, n/a-n/a.	0.9	4
99	Complexity of Medication Use in Newly Diagnosed Chronic Obstructive Pulmonary Disease Patients. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 110-122.e1.	3.0	10
100	Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. <i>International Journal of Clinical Practice</i> , 2012, 66, 1056-1078.	0.8	140
101	Disease-Specific Patient Reported Outcome Tools for Systemic Lupus Erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 56-65.	1.6	118
102	Comparison of FACT- and EQ-5D-Based Utility Scores in Cancer. <i>Value in Health</i> , 2012, 15, 305-311.	0.1	39
103	Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. <i>Value in Health</i> , 2012, 15, 708-715.	0.1	1,381
104	Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia. <i>Value in Health</i> , 2012, 15, 916-925.	0.1	47
105	Body Image in Patients with Systemic Lupus Erythematosus. <i>International Journal of Behavioral Medicine</i> , 2012, 19, 157-164.	0.8	45
106	The Impact of Medicare Part D on Out-of-Pocket Costs for Prescription Drugs, Medication Utilization, Health Resource Utilization, and Preference-Based Health Utility. <i>Health Services Research</i> , 2011, 46, 1104-1123.	1.0	37
107	Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 26.	1.0	73
108	Prioritizing Comparative-Effectiveness Research Topics via Stakeholder Involvement: An Application in COPD. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 888-892.	2.3	11

#	ARTICLE	IF	CITATIONS
109	Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study. <i>Health Economics (United Kingdom)</i> , 2010, 19, 101-110.	0.8	16
110	An Instrument to Evaluate Pharmacists' Patient Counseling on Herbal and Dietary Supplements. <i>American Journal of Pharmaceutical Education</i> , 2010, 74, 192.	0.7	11
111	Application of directional statistics to health state valuation: A commentary on Craig and Oppe. <i>Social Science and Medicine</i> , 2010, 71, 429-430.	1.8	2
112	Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 4.	1.0	13
113	A Median Model for Predicting United States Population-Based EQ-5D Health State Preferences. <i>Value in Health</i> , 2010, 13, 278-288.	0.1	32
114	Exploring Factors that Influence Informal Caregiving in Medication Management for Home Hospice Patients. <i>Journal of Palliative Medicine</i> , 2010, 13, 1085-1090.	0.6	70
115	Psychometric Properties of the EuroQol-5D and Short Form-6D in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 1209-1216.	1.0	68
116	Comparative effectiveness research: Relevance and applications to pharmacy. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 1278-1286.	0.5	34
117	Coded Cause of Death and Timing of COPD Diagnosis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009, 6, 41-47.	0.7	1
118	Mortality Risk in Patients Receiving Drug Regimens with Theophylline for Chronic Obstructive Pulmonary Disease. <i>Pharmacotherapy</i> , 2009, 29, 1039-1053.	1.2	23
119	A Patient-Based Utility Measure of Health for Clinical Trials of Cancer Therapy Based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. <i>Value in Health</i> , 2009, 12, 977-988.	0.1	22
120	Medication adherence and persistence in the last year of life in COPD patients. <i>Respiratory Medicine</i> , 2009, 103, 525-534.	1.3	47
121	Proxy Assessment of Health-Related Quality of Life in African American and White Respondents With Prostate Cancer. <i>Medical Care</i> , 2009, 47, 176-183.	1.1	31
122	Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease. <i>Archives of Internal Medicine</i> , 2009, 169, 1403.	4.3	46
123	Cost-Effectiveness of Eszopiclone for the Treatment of Adults with Primary Chronic Insomnia. <i>Sleep</i> , 2009, 32, 817-824.	0.6	25
124	Clopidogrel-Associated Bleeding and Related Complications in Patients Undergoing Coronary Artery Bypass Grafting. <i>Pharmacotherapy</i> , 2008, 28, 376-392.	1.2	80
125	Use of a preference-based measure of health (EQ-5D) in COPD and asthma. <i>Respiratory Medicine</i> , 2008, 102, 519-536.	1.3	126
126	Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2008, 149, 380.	2.0	151

#	ARTICLE	IF	CITATIONS
127	Conceptual Development of a Measure to Assess Pharmacists' Knowledge of Herbal and Dietary Supplements. American Journal of Pharmaceutical Education, 2008, 72, 59.	0.7	5
128	Evaluating Equivalency Between Response Systems. Medical Care, 2007, 45, 812-819.	1.1	51
129	Psychometric Comparison of the Standard EQ-5D to a 5 Level Version in Cancer Patients. Medical Care, 2007, 45, 259-263.	1.1	205
130	Osteoarthritis: A Comorbid Marker for Longer Life?. Annals of Epidemiology, 2007, 17, 380-384.	0.9	24
131	Pain and depression in caregivers affected their perception of pain in stroke patients. Journal of Clinical Epidemiology, 2007, 60, 963-970.	2.4	30
132	Bisphosphonate-Induced Osteonecrosis of the Jaw. Annals of Pharmacotherapy, 2007, 41, 276-284.	0.9	52
133	Health Utilities Using the EQ-5D in Studies of Cancer. Pharmacoeconomics, 2007, 25, 365-384.	1.7	232
134	Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality of Life Outcomes, 2007, 5, 70.	1.0	672
135	Estimation of Patient Preference-Based Utility Weights from the Functional Assessment of Cancer Therapy™ General. Value in Health, 2007, 10, 266-272.	0.1	61
136	Meta-Analysis of Azelastine Nasal Spray for the Treatment of Allergic Rhinitis. Pharmacotherapy, 2007, 27, 852-859.	1.2	28
137	Eliciting Social Preference Weights for Functional Assessment of Cancer Therapy-Lung Health States. Pharmacoeconomics, 2006, 24, 293-294.	1.7	6
138	An Update on Evidence of Clinical Pharmacy Services™ Impact on Health-Related Quality of Life. Annals of Pharmacotherapy, 2006, 40, 1623-1634.	0.9	46
139	A Comparison of Depressive Symptoms in Stroke and Primary Care: Applying Rasch Models to Evaluate the Center for Epidemiologic Studies-Depression Scale. Value in Health, 2006, 9, 59-64.	0.1	42
140	Towards supporting scholarship in research by clinical pharmacy faculty. Pharmacy Practice, 2006, 4, 191-4.	0.8	8
141	RESPONSE: Re: A Structured Review of Studies on Health-Related Quality of Life and Economic Evaluation in Pediatric Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2005, 97, 1786-1787.	3.0	1
142	Proxy Evaluation of Health-Related Quality of Life. Medical Care, 2005, 43, 493-499.	1.1	189
143	Visual Analog Scales for Assessing Surgical Pain. Journal of the American College of Surgeons, 2005, 201, 245-252.	0.2	123
144	Assessment of Patient Functional Status after Surgery. Journal of the American College of Surgeons, 2005, 201, 171-178.	0.2	139

#	ARTICLE	IF	CITATIONS
145	Responsiveness of generic health-related quality of life measures in stroke. <i>Quality of Life Research</i> , 2005, 14, 207-219.	1.5	139
146	Caveat Medicus: Consequences of Federal Investigations of Marketing Activities of Pharmaceutical Suppliers of Prostate Cancer Drugs. <i>Journal of Clinical Oncology</i> , 2005, 23, 8894-8905.	0.8	10
147	Opportunities for Disease State Management in Prostate Cancer. <i>Disease Management: DM</i> , 2005, 8, 235-244.	1.0	6
148	Costs and Cost Effectiveness of a Health Care Providerâ€‘Directed Intervention to Promote Colorectal Cancer Screening Among Veterans. <i>Journal of Clinical Oncology</i> , 2005, 23, 8877-8883.	0.8	34
149	Granulocyte Colony-Stimulating Factor for Chemotherapy-Induced Neutropenia in Patients with Small Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2005, 23, 767-775.	1.7	16
150	Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?. <i>Health and Quality of Life Outcomes</i> , 2005, 3, 11.	1.0	51
151	Patient Preferences in Prostate Cancer: A Clinician's Guide to Understanding Health Utilities. <i>Clinical Prostate Cancer</i> , 2005, 4, 15-23.	2.1	22
152	Importation of Prescription Medications: Experiences Opinions, and Intended Behaviors of U.S. Community Pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, 666-672.	0.7	0
153	A Structured Review of Studies on Health-Related Quality of Life and Economic Evaluation in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute Monographs</i> , 2004, 2004, 102-125.	0.9	56
154	Agreement Between Patient and Proxy Assessments of Health-Related Quality of Life After Stroke Using the EQ-5D and Health Utilities Index. <i>Stroke</i> , 2004, 35, 607-612.	1.0	165
155	Impact of Oral Direct Thrombin Inhibitors on Anticoagulation Clinics. <i>Pharmacotherapy</i> , 2004, 24, 1204-1212.	1.2	5
156	A Structured Review of the Relationship Between Microalbuminuria and Cardiovascular Events in Patients with Diabetes Mellitus and Hypertension. <i>Pharmacotherapy</i> , 2003, 23, 1611-1616.	1.2	27
157	Edmonton Quality Assessment Tool for Drug Utilization Reviews: EQUATDUR-2. <i>Medical Care</i> , 2000, 38, 948-958.	1.1	3
158	Comparison of the EQ-5D and SF-12 Health Surveys in a General Population Survey in Alberta, Canada. <i>Medical Care</i> , 2000, 38, 115-121.	1.1	240
159	Replicability of SF-36 Summary Scores by the SF-12 in Stroke Patients. <i>Stroke</i> , 1999, 30, 1213-1217.	1.0	107
160	Drug utilization reviews of oral quinolone, cephalosporin, and macrolide use in nonacute care: A systematic review. <i>Clinical Therapeutics</i> , 1999, 21, 1951-1970.	1.1	5
161	The Impact of Pharmacist Interventions on Health-Related Quality of Life. <i>Annals of Pharmacotherapy</i> , 1999, 33, 1167-1172.	0.9	38